The Burrill Report
The Burrill Report (November 26, 2012): Questioning Values (.MP3,17.31 Mb)
The move of healthcare systems around the world to value-based care from fee-for-service models is adding to the financial pressures the pharmaceutical industry faces. Drugmakers will need to rethink their approach to R&D, clinical strategies, and sales and marketing as physicians, patients, and payers demand proof that their new products deliver value for the money. We spoke to Steve Arlington, global pharmaceutical and life sciences advisory leader at PriceWaterhouseCoopers, about the firm’s new Pharma 2020 report, what drugmakers will need to do to drive product success, and why, despite all of the challenges the industry faces, he remains optimistic.
November 21, 2012